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Abstract 
Synthetic glucocorticoids are frequently used antenatally in order to reduce morbidity and 
mortality in babies born preterm and have been used in the management of fetuses known to 
be at risk of congenital adrenal hyperplasia. Although such treatment has short term 
advantages, evidence suggests that it can affect health in later life. Several studies have 
reported negative consequences of prenatal exposure to the synthetic glucocorticoid 
dexamethasone on offspring behaviour in humans and in animal models, in association with 
changes in brain structure, hypothalamic-pituitary-adrenal axis function, neurotransmitter 
pathways, gene transcription and epigenetic regulation. These studies also highlight the 
importance of timing and tissue/organ- and sex-specific effects of prenatal glucocorticoid 
exposure. Here we review the evidence from human and animal studies that links prenatal 
synthetic glucocorticoid exposure with an increased risk for neurodevelopmental disorders.  
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Introduction 
The concept of ‘early life programming’ is used to describe the association between 
environmental factors that occur during early life (pre- or postnatal) and an increased risk of 
diseases in later life [1]. According to this theory, environmental insults occurring at critical 
developmental periods can permanently alter the physiology and function of developing 
organs, resulting in lifelong consequences for health [2]. Such developmental plasticity has 
been proposed to help the unborn animal to optimize its body systems for better survival in a 
predicted adverse postnatal environment, however if the expected environment does not 
match the real postnatal environment, it may lead to malfunction and disease [3].  
 
Physiological responses to environmental adversities are mediated by the hypothalamic-
pituitary-adrenal (HPA) axis, which controls circulating glucocorticoid (GC) concentrations. 
Dysregulation of the HPA axis is associated with several neurodevelopmental disorders 
including autism [4] and schizophrenia [5]. Circulating GC levels are lower in the fetus 
compared to its mother as a consequence of the action of the enzyme 11β-hydroxysteroid 
dehydrogenase type 2 (11β- HSD2) at the fetoplacental barrier, which catalyses the 
conversion of active GC (e.g. cortisol in humans and corticosterone in rodents) into their 
inactive forms (cortisone and 11-dehydrocorticosterone), and thus protects the fetus. 
Nevertheless, this barrier is not complete, and high levels of maternal GC can overcome this 
enzymatic protection [6]; indeed, fetal exposure to elevated levels of maternal GC, as a 
consequence of maternal stress during pregnancy, may impact on the developing brain and 
result in permanent changes in brain function [7].  
 
In addition to exposure to increased endogenous GC levels following maternal stress, fetuses 
can also be exposed to high levels of synthetic GC (sGC), e.g. dexamethasone (DEX) or 
betamethasone, which are frequently administrated to mothers at risk of preterm delivery 
because of the clear benefits of GC on organ maturation, particularly the fetal lung [8]. sGC 
are additionally used in the management of fetuses at risk of (or diagnosed with) congenital 
adrenal hyperplasia to suppress fetal androgen production [9]. Such sGC are poor substrates 
for the 11β-HSD2 enzyme, and can readily cross the placental barrier. In this short review, 
we focus on the effects of prenatal sGC exposure on the brain, including effects on brain 
function and the epigenome. 
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Effects of prenatal glucocorticoid exposure on behaviour  
Although prenatal DEX exposure has been associated with a decrease in the rate of cerebral 
palsy in preterm infants [10], it has also been associated with an increased risk of anxiety, 
hyperactivity and distractibility in preterm and term born children [10–12], with females 
being more susceptible to stress than males [11]. Nevertheless, reports on the outcomes of 
GC overexposure during early life are sometimes contradictory; for example, a long-term 
follow-up study of Swedish children who were prenatally treated with DEX showed no 
changes in psychopathology, behavioral problems or adaptive functioning, on the contrary 
they were described by their parents as being more sociable than the controls [13].  
 
The difficulties in undertaking long-term follow-up studies in humans have led to the 
development of animal models for the study of effects of prenatal exposure to sGC. The 
majority of these models use DEX administration to pregnant dams, however the 
programmed phenotypes depend critically on the timing of exposure. In marmoset monkeys, 
juveniles exposed to early DEX (gestation day 42-48; gestation length ~148 days) were less 
sociable and more motivated to obtain a palatable reward, whereas later DEX treatment (from 
Day 90-96 of gestation) enhanced reversal learning of stimulus association. Offspring of both 
treatment groups showed a deficit in skilled motor reaching, however the effect was stronger 
with late DEX treatment [14].  
 
In rats, DEX administration during the last week of gestation increased acoustic startle 
responses (ASR) in animals which had undergone prior blood sampling [15], suggesting that 
DEX offspring are more susceptible to anxiety [15]. Other studies also show DEX-exposed 
rats spend less time on the open arms of an elevated plus maze (EPM) [16,17] and spend less 
time in the central area of an open field test (OFT) with increased defecation and decreased 
exploratory activity [16,18,19], consistent with a phenotype of hyperanxiety. However, 
experimental findings vary in this field. Very recently, we have shown that DEX-exposed 
male rats demonstrate altered cognition in the Morris water maze [20], but no behavioural 
differences on an EPM or OFT (Table 1). 
 
Overall, these studies suggest that prenatal DEX exposure programs an anxious phenotype, 
however the timing and dose of the DEX administered to the pregnant dams and the age and 
sex of the offspring may be crucial in determining any later effects.  
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Prenatal sGC exposure and brain development 
sGC can exert effects by binding to the glucocorticoid receptor (GR) and mineralocorticoid 
receptor (MR), although they have a higher affinity for GR. Glucocorticoid receptors (GR) 
are widely expressed in the brain from early in prenatal development [21,22], especially in 
the hippocampus [21], explaining why prenatal exposure to sGC could have a significant 
impact on brain development [23]. Indeed, prenatal or postnatal sGC administration in 
rodents and humans significantly reduces brain weight [24,25] and produces structural 
changes in brain regions including the prefrontal cortex (PFC) [26], amygdala [27], 
hippocampus [28] and striatum [29] (Figure 1).  
 
The hippocampus may be particularly vulnerable to prenatal sGC exposure: several studies 
report that prenatal DEX exposure increases apoptosis in hippocampal structures (Dentate 
Gyrus and Cornu Ammonal (CA)) in rats [29,30]. In mice prenatal DEX exposure reduces 
hippocampal volume and increases apoptosis, however these effects do not persist until 
adulthood, whereas it induces a permanent proliferation deficit in the adult hippocampus [28]. 
In rats, prenatal, but not postnatal DEX increases cleaved caspase-3, a marker of apoptosis, in 
the CA1 and CA3 regions of the hippocampus, particularly in females [27].  
 
Some studies suggest that the effects of prenatal DEX exposure can be both detrimental and 
protective within the same organism. For example, one study reports prenatal exposure to 
DEX prevents the increased vascularization observed in the amygdala after chronic stress 
exposure but exacerbates the retraction of vascularization in the hippocampus [19]. In another 
study, fetal exposure to DEX in mice resulted in a decrease in blood vessel density and 
impaired blood-brain barrier in the hypothalamus, whereas it enhances the barrier integrity in 
the cortex [31].  
 
Furthermore, prenatal exposure to DEX in rats correlates with an increased volume and 
increased dendritic length of the bed nucleus of the stria terminalis (BNST), which is 
involved in fear responses. In contrast, prenatal exposure to DEX results in reduced volume 
of the amygdala due to dendritic length diminution [17]. In addition, prenatal DEX exposure 
in rats is also associated with a smaller volume and reduced cell number in the nucleus 
accumbens (NAcc), a heterogenous structure belonging to the striatum which is involved in 
the “reward pathway” and drug addiction [32]. Interestingly, this effect is stronger in males 
than females, which may be relevant to the increased vulnerability of males to drug addiction 
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[33]. Thus, prenatal DEX exposure affects the development of the brain, and the effect can be 
negative or positive depending on the specific region of the brain.  
 
Prenatal sGC exposure and HPA axis regulation 
Several studies suggest that prenatal DEX exposure alters GR expression in the brain, in 
association with changes in HPA axis regulation [18]. In marmosets, late gestation DEX 
exposure leads to a decrease in GR mRNA expression but no effect on MR expression in the 
PFC, both in neonates and in adulthood [34]. In rats, prenatal DEX decreases GR expression 
in the hippocampus [35], whereas in guinea pigs GR expression is decreased [36]. In 
addition, following a 1 hour-recovery from a restraint stress, prenatally DEX-exposed rats 
demonstrate reduced GR mRNA expression in the pituitary gland, whilst control rats have 
increased GR mRNA expression [37]. Moreover, in rats and guinea pigs, offspring of DEX-
treated dams have increased mRNA levels of the corticotrophin-releasing hormone (CRH), a 
critical coordinator of the HPA axis, in the PVN of the hypothalamus [35–37], indicating that 
prenatal DEX leads to persistent changes in HPA axis regulation. CRH is normally released 
by the hypothalamus following a stressor, and acts synergistically with arginine vasopressin 
(AVP) to induce the production of adrenocorticotrophic hormone (ACTH) by the pituitary. 
ACTH then stimulates the production of corticosterone by the adrenal gland, inducing the 
negative feedback loop (Figure 1). 
 
In rats, maternal adrenalectomy, which removes endogenous glucocorticoids, induces a 
depression-like phenotype in the offspring when assessed using the OFT and FST and is 
associated with increased GR expression in the hippocampus and decreased GR expression in 
the hypothalamus [38]. Whilst supplementation with high-dose corticosterone (CORT) 
following adrenalectomy during pregnancy restores normal GR expression in the 
hippocampus, it still results in HPA axis dysregulation. Interestingly, there is a sex-specific 
effect in that although both sexes had an exaggerated plasma ACTH response to stress, only 
females show a reversal of the effect following high dose CORT substitution [38]. 
 
Prenatal sGC exposure and the neurotransmitters 
Several neurotransmitters are important for HPA axis regulation and mood, and are altered 
following prenatal sGC exposure, including the serotonergic, dopaminergic and GABAergic 
systems (Figure 2). Prenatal DEX treatment leads to decreased serotonin (5-HT) 
concentrations in the hippocampus, decreased mRNA expression of the serotonin receptor 5-
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HT1A-R in the PFC and decreased protein expression of brain-derived neurotrophic factor 
(BDNF), which is implicated in the pathogenesis of depression [39], in the PFC and 
hippocampus. Interestingly, early intervention with fluoxetine reverses the dysregulation of 
5-HT signaling as well as the behavioral phenotype in the prenatally DEX-exposed offspring 
[39]. However, a separate study showed that prenatal DEX induces an increase in 5-HT in the 
cortex and hippocampus [40]. The discrepancies might be explained by the different timing 
of DEX exposure between studies, e.g. exposure to DEX daily throughout pregnancy [40] 
versus exposure only during the final week of gestation [41]. In addition, the depressive-like 
phenotype induced by prenatal DEX exposure in rats correlates with a decrease in dopamine 
(DA) in the NAcc and amygdala and this is partially rescued by a treatment with L-3,4-
dihydroxyphenylacetic acid (L-DOPA) [42]. Finally, prenatal DEX exposure in rats decreases 
calretinin expression, a calcium binding protein (CBP) that is expressed in GABAergic 
neurons, in the amygdala of adult female, but not male offspring [24]. 
 
Epigenetic dysregulation and prenatal programming of the brain 
The mechanisms by which the effects of prenatal exposure to stressors are established and 
sustained are not well understood. Epigenetic dysregulation may provide a plausible link 
between early life adversity (including sGC exposure) and sustained alterations in gene 
expression that lead to adulthood diseases [43]. Recent studies suggest epigenetic 
mechanisms such as DNA methylation or histone modifications are involved in the 
development of neuropsychiatric disorders [44,45]. In addition, the developmental period is a 
time when major epigenetic remodelling events occur [46], especially in the brain [47], which 
renders it a time of particular susceptibility to epigenetic re-programming,.  
 
Animal studies suggest that prenatal GC overexposure can induce epigenetic changes in a 
number of candidate genes implicated in neuropsychiatric disorders, including the glutamic 
acid decarboxylase (GAD67), reelin and BDNF genes [48–50]. Prenatal DEX exposure in 
rats leads to a reduction in the protein and mRNA levels of reelin and GAD67 and associates 
with an overexpression of DNA methyltransferase 1 (DNMT1) in the hippocampus [49]. 
Melatonin restores the level of reelin and GAD67 by reducing DNMT1 mRNA expression 
and thus reducing the binding of DNMT1 and methyl-CpG binding protein 2 (MeCP2) to the 
reelin promoter. This result is supported by another study showing that an increase in 
DNMT1 following maternal stress leads to hypermethylation at specific CpG-rich regions of 
the GAD67 and reelin promoters, associated with decreased expression of both genes [50]. 
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Similar results were obtained in another recent study which reported that prenatal stress leads 
to decreased cortical expression of reelin, accompanied by hypermethylation at the reelin 
promoter region. These molecular changes were associated with persistent behavioral 
consequences in adults, such as increased spontaneous locomotor activity, high anxiety levels 
and cognitive deficits [48]. sGC treatment during late gestation in guinea pigs induces 
genome-wide epigenetic changes in promoter methylation and histone acetylation in the fetal 
hippocampus [51,52]. The same group also reported changes in the developmental trajectory 
of DNA methylation in several other fetal tissues in prenatally exposed guinea pigs, which 
has been associated with altered expression of genes involved in the DNA methylation 
process. Furthermore, these effects persisted into adulthood and were transmitted to the next 
generation [52]. 
 
Conclusions and suggestions for further work 
Prenatal sGC exposure associates with altered behavior and increased neurodevelopmental 
disease risk. Importantly, these effects depend highly on the timing of exposure and may be 
sex-specific [24,32,38] with females being more susceptible to stress and a depression-like 
phenotype than males [11,53]. Additionally, the discrepancies between studies using the same 
behavioral tests in animal models suggests that other factors such as animal housing and 
external stressors can affect the outcome [54,55]. There is increasing evidence suggesting a 
role for epigenetic dysregulation in prenatal sGC programming; future in vivo studies could 
be designed to elucidate the consequences of prenatal sGC on the level/activity of epigenetic 
regulators, e.g. the Dnmts, the ten-eleven-translocase (TET) proteins that are involved in the 
generation of cytosine 5-hydroxymethylation (5hmC) and the polycomb-group proteins 
regulating histone marks. Further, studies which delineate the effects on genome wide 
patterns of 5-methylcytosine, 5hmC and histone modifications in dissected brain regions will 
help to elucidate the mechanisms by which prenatal sGC exposure induces long-lasting 
effects on the phenotype.  
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Figure 1: The different components of the brain and their roles in behaviour and the HPA axis 
negative feed-back loop (in italics). CRH: Corticotrophin Realease Hormone, ACTH: 
AdrenoCorticoTropic Hormone, CORT: corticosterone, PFC: Pre-frontal cortex, NAcc: 
Nucleus Accumbens. 
 
 
Figure 2: Neurotransmitter pathways implicated in mood balance and dysregulation in the 
offspring from DEX-treated mothers (black arrow).  
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Test% Measure% Descrip.on% Prenatal%DEX%eﬀects% References%
Open%Field%Test% Anxiety%
Large%open%area%with%wall%
where%the%locomo9on%and%
the%willingness%of%the%
animal%to%explore%is%
measured%
decreased%
locomo9on%and%
explora9on%ac9vity%
17.18.19%
%
no%diﬀerences% Zeng%et%al%
Elevated%plus%maze% Anxiety%
The%test%seFng%consists%of%
a%plusGshaped%apparatus%
with%two%open%and%two%
enclosed%arms,%each%with%
an%open%roof,%elevated%
40–70%cm%from%the%ﬂoor.%
The%model%is%based%on%
rodents'%aversion%of%open%
spaces.%
Animals%spend%less%
9me%in%the%open%
arms%
16.18%
no%diﬀerences% Zeng%et%al%
Morris%water%maze% spa9al%learning%and%memory%
The%rat%is%placed%in%a%large%
circular%pool%and%is%
supposed%to%ﬁnd%an%
invisible%or%visible%plaRorm%
that%allows%it%to%escape%
the%water%by%using%various%
cues%
animal%slower%the%
ﬁrst%day%of%trial%
then%faster%to%
locate%the%plaRorm%
Zeng%et%al%
no%diﬀerences% 18%
Force%Swim%Test% depression%
Animals%are%forced%to%
swim%in%an%acrylic%glass%
cylinder%ﬁll%with%water%
several%9mes.%%
increased%
immobility% 15.18%
no%diﬀerences% 17%
Table1:%Behavioural%tests%and%the%consequences%of%prenatal%DEX%exposure%
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